Last reviewed · How we verify

Budesonide / Formoterol — Competitive Intelligence Brief

Budesonide / Formoterol (Budesonide / Formoterol) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inhaled corticosteroid / long-acting beta-2 agonist combination. Area: Respiratory / Pulmonology.

marketed Inhaled corticosteroid / long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Budesonide / Formoterol (Budesonide / Formoterol) — Brigham and Women's Hospital. Budesonide reduces airway inflammation via glucocorticoid receptor activation, while formoterol dilates airways by activating beta-2 adrenergic receptors.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Budesonide / Formoterol TARGET Budesonide / Formoterol Brigham and Women's Hospital marketed Inhaled corticosteroid / long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
RELVAR/BREO RELVAR/BREO GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Symbicort Turbohaler without Turbo+ Symbicort Turbohaler without Turbo+ Istituto per la Ricerca e l'Innovazione Biomedica marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
FF FF GlaxoSmithKline marketed Inhaled corticosteroid/long-acting beta-2 agonist (ICS/LABA) combination Glucocorticoid receptor; beta-2 adrenergic receptor
CHF1535 CHF1535 Chiesi Farmaceutici S.p.A. marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
Budesonide/formoterol Turbuhaler Budesonide/formoterol Turbuhaler AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor
budesonide/formoterol Turbuhaler 320/9µg budesonide/formoterol Turbuhaler 320/9µg AstraZeneca marketed Inhaled corticosteroid/long-acting beta-2 agonist combination Glucocorticoid receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inhaled corticosteroid / long-acting beta-2 agonist combination class)

  1. Brigham and Women's Hospital · 1 drug in this class
  2. EMS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budesonide / Formoterol — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-formoterol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: